A citation-based method for searching scientific literature

J K Morris, G L Bomhoff, B K Gorres, V A Davis, J Kim, P-P Lee, W M Brooks, G A Gerhardt, P C Geiger, J A Stanford. Exp Neurol 2011
Times Cited: 91







List of co-cited articles
1286 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
278
36

Type 2 diabetes and the risk of Parkinson's disease.
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen, Jaakko Tuomilehto. Diabetes Care 2007
289
35

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
405
34

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.
I Moroo, T Yamada, H Makino, I Tooyama, P L McGeer, E G McGeer, K Hirayama. Acta Neuropathol 1994
115
31

Parkinson's disease, insulin resistance and novel agents of neuroprotection.
Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees, Thomas Foltynie. Brain 2013
185
28

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
240
28

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
190
26

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
160
25

Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet.
Jill K Morris, Gregory L Bomhoff, John A Stanford, Paige C Geiger. Am J Physiol Regul Integr Comp Physiol 2010
88
25

Diabetes and risk of Parkinson's disease.
Qun Xu, Yikyung Park, Xuemei Huang, Albert Hollenbeck, Aaron Blair, Arthur Schatzkin, Honglei Chen. Diabetes Care 2011
163
23

Diabetes and the risk of developing Parkinson's disease in Denmark.
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth, Beate Ritz. Diabetes Care 2011
117
23

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
467
23

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
339
21


Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Mark L Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee, Hsin-Ni Tsai. Parkinsonism Relat Disord 2012
145
20


Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease.
J K Morris, H Zhang, A A Gupte, G L Bomhoff, J A Stanford, P C Geiger. Brain Res 2008
47
38

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
229
19

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
19

Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications.
Yu Sun, Ya-Hui Chang, Hua-Fen Chen, Ying-Hwa Su, Hui-Fang Su, Chung-Yi Li. Diabetes Care 2012
121
18

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
811
17


Dementia is associated with insulin resistance in patients with Parkinson's disease.
Domenico Bosco, Massimiliano Plastino, Dario Cristiano, Carmela Colica, Caterina Ermio, Matteo De Bartolo, Pasquale Mungari, Giulia Fonte, Domenico Consoli, Arturo Consoli,[...]. J Neurol Sci 2012
80
18

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
137
16

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.
Jessica Freiherr, Manfred Hallschmid, William H Frey, Yvonne F Brünner, Colin D Chapman, Christian Hölscher, Suzanne Craft, Fernanda G De Felice, Christian Benedict. CNS Drugs 2013
308
16

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
576
16

Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice.
Ling Wang, Ying-Qi Zhai, Li-Li Xu, Chen Qiao, Xiu-Lan Sun, Jian-Hua Ding, Ming Lu, Gang Hu. Exp Neurol 2014
63
23

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
16

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.
Aileen M Moloney, Rebecca J Griffin, Suzanne Timmons, Rosemary O'Connor, Rivka Ravid, Cora O'Neill. Neurobiol Aging 2010
518
14

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
254
14

The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
Caitriona M Long-Smith, Sean Manning, Paula L McClean, Meghan F Coakley, Domhnall J O'Halloran, Christian Holscher, Cora O'Neill. Neuromolecular Med 2013
107
14

Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease.
Jane A Driver, Ashley Smith, Julie E Buring, J Michael Gaziano, Tobias Kurth, Giancarlo Logroscino. Diabetes Care 2008
105
13

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
589
13

Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity.
Ji-Young Choi, Eun-Hee Jang, Chang-Shin Park, Ju-Hee Kang. Free Radic Biol Med 2005
69
17


Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
E Cereda, M Barichella, E Cassani, R Caccialanza, G Pezzoli. Neurology 2012
90
13


Insulin receptor mRNA in the substantia nigra in Parkinson's disease.
M Takahashi, T Yamada, I Tooyama, I Moroo, H Kimura, T Yamamoto, H Okada. Neurosci Lett 1996
89
12


Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan.
Yoshihiro Miyake, Keiko Tanaka, Wakaba Fukushima, Satoshi Sasaki, Chikako Kiyohara, Yoshio Tsuboi, Tatsuo Yamada, Tomoko Oeda, Takami Miki, Nobutoshi Kawamura,[...]. J Neurol Sci 2010
84
13

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.
Abba J Kastin, Victoria Akerstrom, Weihong Pan. J Mol Neurosci 2002
343
12

Shared dysregulated pathways lead to Parkinson's disease and diabetes.
Jose A Santiago, Judith A Potashkin. Trends Mol Med 2013
137
12

Obesity, diabetes, and risk of Parkinson's disease.
Natalia Palacios, Xiang Gao, Marjorie L McCullough, Eric J Jacobs, Alpa V Patel, Tinisha Mayo, Michael A Schwarzschild, Alberto Ascherio. Mov Disord 2011
98
12

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
319
12

A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
Lijun Cao, Dongfang Li, Peng Feng, Lin Li, Guo-Fang Xue, Guanglai Li, Christian Hölscher. Neuroreport 2016
48
22


Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
Eric Steen, Benjamin M Terry, Enrique J Rivera, Jennifer L Cannon, Thomas R Neely, Rose Tavares, X Julia Xu, Jack R Wands, Suzanne M de la Monte. J Alzheimers Dis 2005
10

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
A Hamilton, S Patterson, D Porter, V A Gault, C Holscher. J Neurosci Res 2011
150
10

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
TracyAnn Perry, Debomoy K Lahiri, Kumar Sambamurti, Demao Chen, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Neurosci Res 2003
271
10

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.
Bin Zheng, Zhixiang Liao, Joseph J Locascio, Kristen A Lesniak, Sarah S Roderick, Marla L Watt, Aron C Eklund, Yanli Zhang-James, Peter D Kim, Michael A Hauser,[...]. Sci Transl Med 2010
530
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.